One of the largest shares of preclinical testing in any drug development program is toxicology studies, yet bringing together the community supporting this pivotal development stage does not happen often enough. Fortunately, the 2020 American College of Toxicology (ACT) Annual Meeting is occurring this year on a virtual stage. It is set to be an engaging event that will allow this community to reconnect over industry insights and program support.
The drug development industry is continuously evolving; innovation never halts. Between toxicologists, consultants, students and more, the ability to advance progress relies on collaboration. The trials of the past year have made connection on a large scale difficult, but the 2020 ACT brings together various backgrounds to learn and improve drug safety globally.
Improving drug development programs starts with identifying underlying obstacles, which sometimes requires an outside perspective. Experts at laboratory testing facilities face these head-on every day. At the upcoming ACT meeting, WuXi AppTec’s experts will present, “Challenges to Drug Development in an Evolving International Marketplace,” sharing the latest insights on common issues like changes to preclinical testing, the Investigational New Drug (IND) process, designing a preclinical program strategy and other trending industry topics.
Many developers have updated established drug development processes, and while many teams have settled back into routines – modifications to enhance your typical approach should not let up. Some obstacles are in your control as a drug developer, like defining a clinical plan or dosing schedule, and our ACT 2020 presentation can help your current or new programs.
When uncontrollable factors impact projected timelines, such as delays from capacity or test system shortages, they do not need to be faced alone. Partners with exposure to various global programs can contribute to identifying efficiencies and closing timeline gaps.
If you are attending the 2020 ACT Annual Meeting, please join us for our presentation on November 12th at 10:00 am CT to learn how to maximize your success in drug development and identify how to mitigate delays while proactively assuring high-quality results. For more information, check out our virtual booth and schedule an exclusive, one-on-one meeting with an expert by filling out the form below.
For additional industry insights and program support, check out the WuXi AppTec Laboratory Testing Division LinkedIn and blog pages.
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,000 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated”.
